↓ Skip to main content

Pure anti-tumor effect of zoledronic acid in naïve bone-only metastatic and locally advanced breast cancer: proof from the “biological window therapy”

Overview of attention for article published in Breast Cancer Research and Treatment, January 2014
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
3 X users

Citations

dimensions_citation
14 Dimensions

Readers on

mendeley
35 Mendeley
Title
Pure anti-tumor effect of zoledronic acid in naïve bone-only metastatic and locally advanced breast cancer: proof from the “biological window therapy”
Published in
Breast Cancer Research and Treatment, January 2014
DOI 10.1007/s10549-014-2840-y
Pubmed ID
Authors

Chiara Foroni, Manuela Milan, Carla Strina, Mariarosa Cappelletti, Claudia Fumarola, Mara Bonelli, Ramona Bertoni, Giuseppina Ferrero, Mara Maldotti, Elena Takano, Daniele Andreis, Sergio Venturini, Giulia Brugnoli, Pier Giorgio Petronini, Vanessa Zanoni, Laura Pritzker, Kenneth Pritzker, Amadeo Parissenti, Daniele Santini, Stephen B. Fox, Alberto Bottini, Daniele Generali

Abstract

The study investigated the anti-tumour effect of zoledronic acid (ZA) administered alone in a biological window therapy in naïve bone-only metastatic and locally advanced breast cancer (LABC) patients. 33 patients with LABC (Group 1) and 20 patients with a first diagnosis of bone metastasis only (Group 2) received 4 mg single dose of ZA, 14 days (biological window) before starting any treatment. In Group 1, Ki67, CD34, p53/bcl-2 and caspase 3 expression along with the adenosine triphosphate (ATP) levels and RNA disruption index were evaluated as markers of tumor growth in tumour specimens obtained before and after ZA administration (basal, day 14). In Group 2, the total enumeration of circulating tumour cells (CTCs), and of M30+ve CTCs along with the soluble marker of cell death (M30/M65) were carried-out as markers of tumor dissemination at baseline, at 48 h and day 14th. In Group 1, there was a significant reduction in Ki67, CD34, bcl-2 expression after 14 days ZA based-treatment (p = 0.0032; p = 0.0001, p < 0.00001 respectively). ZA showed a significant increase of RNA disruption (p < 0.0076). In Group 2, we observed a significant reduction of CTCs number after 48 h (p = 0.0012), followed by a significant rebound at 14 days (p = 0.012). The apoptotic CTCs/M30+ve and M65 levels significantly increased under treatment (p = 0.018 and p = 0.039 respectively) after drug administration when compared to the baseline. These results are the first prospective in vivo data showing the direct pure anti-tumour effect (either on the tumour cell or on CTCs) of ZA.

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 35 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Italy 1 3%
Unknown 34 97%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 6 17%
Other 5 14%
Researcher 5 14%
Lecturer 3 9%
Student > Bachelor 2 6%
Other 6 17%
Unknown 8 23%
Readers by discipline Count As %
Medicine and Dentistry 16 46%
Agricultural and Biological Sciences 3 9%
Unspecified 2 6%
Nursing and Health Professions 2 6%
Immunology and Microbiology 2 6%
Other 1 3%
Unknown 9 26%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 February 2014.
All research outputs
#13,707,147
of 22,743,667 outputs
Outputs from Breast Cancer Research and Treatment
#2,971
of 4,651 outputs
Outputs of similar age
#166,821
of 307,481 outputs
Outputs of similar age from Breast Cancer Research and Treatment
#31
of 52 outputs
Altmetric has tracked 22,743,667 research outputs across all sources so far. This one is in the 38th percentile – i.e., 38% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,651 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one is in the 35th percentile – i.e., 35% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 307,481 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 44th percentile – i.e., 44% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 52 others from the same source and published within six weeks on either side of this one. This one is in the 40th percentile – i.e., 40% of its contemporaries scored the same or lower than it.